0.014110 0.000000 0.000000 0.000000 0.011073 0.000000 0.000000 0.000000 0.011307 0.00000 0.00000 0.00000 Roe, S.M. Prodromou, C. Pearl, L.H. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 8 90.00 90.00 90.00 70.870 90.310 88.440 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking H2 O 18.015 WATER non-polymer C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking C16 H13 Cl N2 O4 S 364.803 4-CHLORO-6-[5-(3,4-DIMETHOXYPHENYL)-1,2,3-THIADIAZOL-4-YL]BENZENE-1,3-DIOL non-polymer US Plos One 1932-6203 7 44642 10.1371/JOURNAL.PONE.0044642 22984537 Co-Crystalization and in Vitro Biological Characterization of 5-Aryl-4-(5-Substituted-2-4-Dihydroxyphenyl)-1,2,3-Thiadiazole Hsp90 Inhibitors. 2012 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 100 1 CCD 2009-05-27 ADSC CCD SINGLE WAVELENGTH M x-ray 1 0.9796 1.0 I02 Diamond 0.9796 SYNCHROTRON DIAMOND BEAMLINE I02 25856.082 HEAT SHOCK PROTEIN HSP 90-ALPHA N-TERMINAL DOMAIN, RESIDUES 1-229 1 man polymer 364.803 4-CHLORO-6-[5-(3,4-DIMETHOXYPHENYL)-1,2,3-THIADIAZOL-4-YL]BENZENE-1,3-DIOL 1 syn non-polymer 18.015 water 107 nat water HEAT SHOCK 86 KDA, HSP 86, HSP86, RENAL CARCINOMA ANTIGEN NY-REN-38, HSP90 no no MPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINL IPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQY AWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKE MPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINL IPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQY AWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKE A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n HUMAN sample 9606 HOMO SAPIENS 562 ESCHERICHIA COLI 1 2.83 57 NONE 7 pH 7 repository Initial release Database references 1 0 2012-05-16 1 1 2012-09-26 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- 2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS. NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR CHAPERONE HSP90 DISCOVERED THROUGH STRUCTURE-BASED DESIGN HUMAN HSP90 IN COMPLEX WITH 17-DESMETHOXY-17-N,N- DIMETHYLAMINOETHYLAMINO-GELDANAMYCIN ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING STRUCTURE-BASED DISCOVERY OF A NEW CLASS OF HSP90 INHIBITORS HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING HUMAN HSP90 WITH 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H- PYRAZOL-3-YL)-BENZENE-1,2-DIOL HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY-BENZYL)-2- FLUORO-9-PENT-9H-PURIN-6-YLAMINE HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4,5- TRIMETHOXY-BENZYL)-2-FLUORO-9-PENT-4-YLNYL-9H-PURIN -6-YLAMINE CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED WITHDIHYDROXYPHENYLPYRAZOLES HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE-4- CARBOXAMIDES AS INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- 2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS. 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT WATERSOLUBLE INHIBITOR PU-H71 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY- BENZYL)-2-FLUORO-9H-PURIN-6-YLAMINE STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT WATERSOLUBLE INHIBITOR PU-H64 HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4,5- TRIMETHOXY-BENZYL)-9-PENT-4-YLNYL-9H-PURIN-6-YLAMINE STRUCTURE-ACTIVITY RELATIONSHIPS IN PURINE-BASED INHIBITOR BINDING TO HSP90 ISOFORMS STRUCTURE OF HSP90 WITH AN INHIBITOR BOUND HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(4-METHOXY-BENZYL )-9H-PURIN-6-YLAMINE STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE-4- CARBOXAMIDES AS INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE HUMAN HSP90 WITH 4-(4-(2,3-DIHYDRO-BENZOL(1,4) DIOXIN-6-YL)-5-METHYL-1H-PYRAZOL-3-YL)-6-ETHYL- BENZENE-1,3-DIOL HUMAN HSP90-ALPHA WITH 8-BENZO[1,3]DIOXOL-,5- YLMETHYL-9-BUTYL-9H-PURIN-6-YLAMINE HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "OPEN" CONFORMATION HSP90 N-TERMINAL DOMAIN BOUND TO ADP-MG STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- 2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS. HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3-TRIMETHOXY- BENZYL)-9H-PURIN-6YLAMINE ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE SOLUTION STRUCTURE OF THE TPR DOMAIN FROM PROTEIN PHOSPHATASE 5 IN COMPLEX WITH HSP90 DERIVED PEPTIDE INHIBITION OF THE HSP90 MOLECULAR CHAPERONE IN VITRO AND IN VIVO BY NOVEL, SYNTHETIC, POTENT RESORCINYLIC PYRAZOLE, ISOXAZOLE AMIDE ANALOGS HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR CHAPERONE HSP90 DISCOVERED THROUGH STRUCTURE-BASED DESIGN HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "CLOSED" CONFORMATION HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY-BENZYL)-2- FLUORO-9H-PURIN-6-YLAMINE HUMAN HSP90 WITH 4-CHLORO-6-(4-(4-(4- METHANESULPHONYL-BENZYL)-PIERAZIN-1-YL)-1H-PYRAZOL-3- YL)-BENZENE-1,3-DIOL STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2-CHLORO-3,4,5 -TRIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3,4,5-TRIMETHOXY -BENZYL)-9H-PURIN-6-YLAMINE HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED WITHDIHYDROXYPHENYLPYRAZOLES HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING CRYSTAL STRUCTURE OF THE CHIP U-BOX E3 UBIQUITIN LIGASE HUMAN HSP90-ALPHA WITH 8-BENZO[1,3]DIOXOL-,5- YLMETHYL-9-BUTYL-2-FLUORO-9H-PURIN-6-YLAMINE HUMAN HSP90 WITH 5-(5-CHLORO-2,4-DIHYDROXY-PHENYL)- 4-PIPERAZIN-1-YL-2H-PYRAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING CRYSTAL STRUCTURES OF HUMAN HSP90ALPHA COMPLEXED WITHDIHYDROXYPHENYLPYRAZOLES HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY- BENZYL)-9H-PURIN-6-YLAMINE GELDANAMYCIN BOUND TO THE HSP90 GELDANAMYCIN-BINDING DOMAIN HSP90 ALPHA ATPASE DOMAIN WITH BOUND SMALL MOLECULE FRAGMENT HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING PDBE Y PDBE 2011-05-10 REL YI5 4-CHLORO-6-[5-(3,4-DIMETHOXYPHENYL)-1,2,3-THIADIAZOL-4-YL]BENZENE-1,3-DIOL HOH water 4-CHLORO-6-[5-(3,4-DIMETHOXYPHENYL)-1,2,3-THIADIAZOL-4- YL]BENZENE-1,3-DIOL (YI5). YI5 1226 2 YI5 YI5 1226 A HOH 2001 3 HOH HOH 2001 A HOH 2002 3 HOH HOH 2002 A HOH 2003 3 HOH HOH 2003 A HOH 2004 3 HOH HOH 2004 A HOH 2005 3 HOH HOH 2005 A HOH 2006 3 HOH HOH 2006 A HOH 2007 3 HOH HOH 2007 A HOH 2008 3 HOH HOH 2008 A HOH 2009 3 HOH HOH 2009 A HOH 2010 3 HOH HOH 2010 A HOH 2011 3 HOH HOH 2011 A HOH 2012 3 HOH HOH 2012 A HOH 2013 3 HOH HOH 2013 A HOH 2014 3 HOH HOH 2014 A HOH 2015 3 HOH HOH 2015 A HOH 2016 3 HOH HOH 2016 A HOH 2017 3 HOH HOH 2017 A HOH 2018 3 HOH HOH 2018 A HOH 2019 3 HOH HOH 2019 A HOH 2020 3 HOH HOH 2020 A HOH 2021 3 HOH HOH 2021 A HOH 2022 3 HOH HOH 2022 A HOH 2023 3 HOH HOH 2023 A HOH 2024 3 HOH HOH 2024 A HOH 2025 3 HOH HOH 2025 A HOH 2026 3 HOH HOH 2026 A HOH 2027 3 HOH HOH 2027 A HOH 2028 3 HOH HOH 2028 A HOH 2029 3 HOH HOH 2029 A HOH 2030 3 HOH HOH 2030 A HOH 2031 3 HOH HOH 2031 A HOH 2032 3 HOH HOH 2032 A HOH 2033 3 HOH HOH 2033 A HOH 2034 3 HOH HOH 2034 A HOH 2035 3 HOH HOH 2035 A HOH 2036 3 HOH HOH 2036 A HOH 2037 3 HOH HOH 2037 A HOH 2038 3 HOH HOH 2038 A HOH 2039 3 HOH HOH 2039 A HOH 2040 3 HOH HOH 2040 A HOH 2041 3 HOH HOH 2041 A HOH 2042 3 HOH HOH 2042 A HOH 2043 3 HOH HOH 2043 A HOH 2044 3 HOH HOH 2044 A HOH 2045 3 HOH HOH 2045 A HOH 2046 3 HOH HOH 2046 A HOH 2047 3 HOH HOH 2047 A HOH 2048 3 HOH HOH 2048 A HOH 2049 3 HOH HOH 2049 A HOH 2050 3 HOH HOH 2050 A HOH 2051 3 HOH HOH 2051 A HOH 2052 3 HOH HOH 2052 A HOH 2053 3 HOH HOH 2053 A HOH 2054 3 HOH HOH 2054 A HOH 2055 3 HOH HOH 2055 A HOH 2056 3 HOH HOH 2056 A HOH 2057 3 HOH HOH 2057 A HOH 2058 3 HOH HOH 2058 A HOH 2059 3 HOH HOH 2059 A HOH 2060 3 HOH HOH 2060 A HOH 2061 3 HOH HOH 2061 A HOH 2062 3 HOH HOH 2062 A HOH 2063 3 HOH HOH 2063 A HOH 2064 3 HOH HOH 2064 A HOH 2065 3 HOH HOH 2065 A HOH 2066 3 HOH HOH 2066 A HOH 2067 3 HOH HOH 2067 A HOH 2068 3 HOH HOH 2068 A HOH 2069 3 HOH HOH 2069 A HOH 2070 3 HOH HOH 2070 A HOH 2071 3 HOH HOH 2071 A HOH 2072 3 HOH HOH 2072 A HOH 2073 3 HOH HOH 2073 A HOH 2074 3 HOH HOH 2074 A HOH 2075 3 HOH HOH 2075 A HOH 2076 3 HOH HOH 2076 A HOH 2077 3 HOH HOH 2077 A HOH 2078 3 HOH HOH 2078 A HOH 2079 3 HOH HOH 2079 A HOH 2080 3 HOH HOH 2080 A HOH 2081 3 HOH HOH 2081 A HOH 2082 3 HOH HOH 2082 A HOH 2083 3 HOH HOH 2083 A HOH 2084 3 HOH HOH 2084 A HOH 2085 3 HOH HOH 2085 A HOH 2086 3 HOH HOH 2086 A HOH 2087 3 HOH HOH 2087 A HOH 2088 3 HOH HOH 2088 A HOH 2089 3 HOH HOH 2089 A HOH 2090 3 HOH HOH 2090 A HOH 2091 3 HOH HOH 2091 A HOH 2092 3 HOH HOH 2092 A HOH 2093 3 HOH HOH 2093 A HOH 2094 3 HOH HOH 2094 A HOH 2095 3 HOH HOH 2095 A HOH 2096 3 HOH HOH 2096 A HOH 2097 3 HOH HOH 2097 A HOH 2098 3 HOH HOH 2098 A HOH 2099 3 HOH HOH 2099 A HOH 2100 3 HOH HOH 2100 A HOH 2101 3 HOH HOH 2101 A HOH 2102 3 HOH HOH 2102 A HOH 2103 3 HOH HOH 2103 A HOH 2104 3 HOH HOH 2104 A HOH 2105 3 HOH HOH 2105 A HOH 2106 3 HOH HOH 2106 A HOH 2107 3 HOH HOH 2107 A n 1 1 A n 2 2 A n 3 3 A n 4 4 A n 5 5 A n 6 6 A n 7 7 A n 8 8 A n 9 9 A n 10 10 A n 11 11 A n 12 12 A n 13 13 A n 14 14 A n 15 15 A GLU 16 n 16 GLU 16 A VAL 17 n 17 VAL 17 A GLU 18 n 18 GLU 18 A THR 19 n 19 THR 19 A PHE 20 n 20 PHE 20 A ALA 21 n 21 ALA 21 A PHE 22 n 22 PHE 22 A GLN 23 n 23 GLN 23 A ALA 24 n 24 ALA 24 A GLU 25 n 25 GLU 25 A ILE 26 n 26 ILE 26 A ALA 27 n 27 ALA 27 A GLN 28 n 28 GLN 28 A LEU 29 n 29 LEU 29 A MET 30 n 30 MET 30 A SER 31 n 31 SER 31 A LEU 32 n 32 LEU 32 A ILE 33 n 33 ILE 33 A ILE 34 n 34 ILE 34 A ASN 35 n 35 ASN 35 A THR 36 n 36 THR 36 A PHE 37 n 37 PHE 37 A TYR 38 n 38 TYR 38 A SER 39 n 39 SER 39 A ASN 40 n 40 ASN 40 A LYS 41 n 41 LYS 41 A GLU 42 n 42 GLU 42 A ILE 43 n 43 ILE 43 A PHE 44 n 44 PHE 44 A LEU 45 n 45 LEU 45 A ARG 46 n 46 ARG 46 A GLU 47 n 47 GLU 47 A LEU 48 n 48 LEU 48 A ILE 49 n 49 ILE 49 A SER 50 n 50 SER 50 A ASN 51 n 51 ASN 51 A SER 52 n 52 SER 52 A SER 53 n 53 SER 53 A ASP 54 n 54 ASP 54 A ALA 55 n 55 ALA 55 A LEU 56 n 56 LEU 56 A ASP 57 n 57 ASP 57 A LYS 58 n 58 LYS 58 A ILE 59 n 59 ILE 59 A ARG 60 n 60 ARG 60 A TYR 61 n 61 TYR 61 A GLU 62 n 62 GLU 62 A SER 63 n 63 SER 63 A LEU 64 n 64 LEU 64 A THR 65 n 65 THR 65 A ASP 66 n 66 ASP 66 A PRO 67 n 67 PRO 67 A SER 68 n 68 SER 68 A LYS 69 n 69 LYS 69 A LEU 70 n 70 LEU 70 A ASP 71 n 71 ASP 71 A SER 72 n 72 SER 72 A GLY 73 n 73 GLY 73 A LYS 74 n 74 LYS 74 A GLU 75 n 75 GLU 75 A LEU 76 n 76 LEU 76 A HIS 77 n 77 HIS 77 A ILE 78 n 78 ILE 78 A ASN 79 n 79 ASN 79 A LEU 80 n 80 LEU 80 A ILE 81 n 81 ILE 81 A PRO 82 n 82 PRO 82 A ASN 83 n 83 ASN 83 A LYS 84 n 84 LYS 84 A GLN 85 n 85 GLN 85 A ASP 86 n 86 ASP 86 A ARG 87 n 87 ARG 87 A THR 88 n 88 THR 88 A LEU 89 n 89 LEU 89 A THR 90 n 90 THR 90 A ILE 91 n 91 ILE 91 A VAL 92 n 92 VAL 92 A ASP 93 n 93 ASP 93 A THR 94 n 94 THR 94 A GLY 95 n 95 GLY 95 A ILE 96 n 96 ILE 96 A GLY 97 n 97 GLY 97 A MET 98 n 98 MET 98 A THR 99 n 99 THR 99 A LYS 100 n 100 LYS 100 A ALA 101 n 101 ALA 101 A ASP 102 n 102 ASP 102 A LEU 103 n 103 LEU 103 A ILE 104 n 104 ILE 104 A ASN 105 n 105 ASN 105 A ASN 106 n 106 ASN 106 A LEU 107 n 107 LEU 107 A GLY 108 n 108 GLY 108 A THR 109 n 109 THR 109 A ILE 110 n 110 ILE 110 A n 111 111 A n 112 112 A n 113 113 A GLY 114 n 114 GLY 114 A THR 115 n 115 THR 115 A LYS 116 n 116 LYS 116 A ALA 117 n 117 ALA 117 A PHE 118 n 118 PHE 118 A MET 119 n 119 MET 119 A GLU 120 n 120 GLU 120 A ALA 121 n 121 ALA 121 A LEU 122 n 122 LEU 122 A GLN 123 n 123 GLN 123 A ALA 124 n 124 ALA 124 A GLY 125 n 125 GLY 125 A ALA 126 n 126 ALA 126 A ASP 127 n 127 ASP 127 A ILE 128 n 128 ILE 128 A SER 129 n 129 SER 129 A MET 130 n 130 MET 130 A ILE 131 n 131 ILE 131 A GLY 132 n 132 GLY 132 A GLN 133 n 133 GLN 133 A PHE 134 n 134 PHE 134 A GLY 135 n 135 GLY 135 A VAL 136 n 136 VAL 136 A GLY 137 n 137 GLY 137 A PHE 138 n 138 PHE 138 A TYR 139 n 139 TYR 139 A SER 140 n 140 SER 140 A ALA 141 n 141 ALA 141 A TYR 142 n 142 TYR 142 A LEU 143 n 143 LEU 143 A VAL 144 n 144 VAL 144 A ALA 145 n 145 ALA 145 A GLU 146 n 146 GLU 146 A LYS 147 n 147 LYS 147 A VAL 148 n 148 VAL 148 A THR 149 n 149 THR 149 A VAL 150 n 150 VAL 150 A ILE 151 n 151 ILE 151 A THR 152 n 152 THR 152 A LYS 153 n 153 LYS 153 A HIS 154 n 154 HIS 154 A ASN 155 n 155 ASN 155 A ASP 156 n 156 ASP 156 A ASP 157 n 157 ASP 157 A GLU 158 n 158 GLU 158 A GLN 159 n 159 GLN 159 A TYR 160 n 160 TYR 160 A ALA 161 n 161 ALA 161 A TRP 162 n 162 TRP 162 A GLU 163 n 163 GLU 163 A SER 164 n 164 SER 164 A SER 165 n 165 SER 165 A ALA 166 n 166 ALA 166 A GLY 167 n 167 GLY 167 A GLY 168 n 168 GLY 168 A SER 169 n 169 SER 169 A PHE 170 n 170 PHE 170 A THR 171 n 171 THR 171 A VAL 172 n 172 VAL 172 A ARG 173 n 173 ARG 173 A THR 174 n 174 THR 174 A ASP 175 n 175 ASP 175 A THR 176 n 176 THR 176 A GLY 177 n 177 GLY 177 A GLU 178 n 178 GLU 178 A PRO 179 n 179 PRO 179 A MET 180 n 180 MET 180 A GLY 181 n 181 GLY 181 A ARG 182 n 182 ARG 182 A GLY 183 n 183 GLY 183 A THR 184 n 184 THR 184 A LYS 185 n 185 LYS 185 A VAL 186 n 186 VAL 186 A ILE 187 n 187 ILE 187 A LEU 188 n 188 LEU 188 A HIS 189 n 189 HIS 189 A LEU 190 n 190 LEU 190 A LYS 191 n 191 LYS 191 A GLU 192 n 192 GLU 192 A ASP 193 n 193 ASP 193 A GLN 194 n 194 GLN 194 A THR 195 n 195 THR 195 A GLU 196 n 196 GLU 196 A TYR 197 n 197 TYR 197 A LEU 198 n 198 LEU 198 A GLU 199 n 199 GLU 199 A GLU 200 n 200 GLU 200 A ARG 201 n 201 ARG 201 A ARG 202 n 202 ARG 202 A ILE 203 n 203 ILE 203 A LYS 204 n 204 LYS 204 A GLU 205 n 205 GLU 205 A ILE 206 n 206 ILE 206 A VAL 207 n 207 VAL 207 A LYS 208 n 208 LYS 208 A LYS 209 n 209 LYS 209 A HIS 210 n 210 HIS 210 A SER 211 n 211 SER 211 A GLN 212 n 212 GLN 212 A PHE 213 n 213 PHE 213 A ILE 214 n 214 ILE 214 A GLY 215 n 215 GLY 215 A TYR 216 n 216 TYR 216 A PRO 217 n 217 PRO 217 A ILE 218 n 218 ILE 218 A THR 219 n 219 THR 219 A LEU 220 n 220 LEU 220 A PHE 221 n 221 PHE 221 A VAL 222 n 222 VAL 222 A GLU 223 n 223 GLU 223 A LYS 224 n 224 LYS 224 A GLU 225 n 225 GLU 225 A n 226 226 A n 227 227 A n 228 228 A n 229 229 A author_and_software_defined_assembly PISA 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N PHE 20 A N PHE 20 A O PHE 170 A O PHE 170 A N ARG 173 A N ARG 173 A O ALA 161 A O ALA 161 A N SER 164 A N SER 164 A O VAL 148 A O VAL 148 A N LYS 153 A N LYS 153 A O GLY 183 A O GLY 183 A N LEU 188 A N LEU 188 A O LEU 89 A O LEU 89 A N VAL 92 A N VAL 92 A O ASN 79 A O ASN 79 A N LEU 80 A N LEU 80 A O THR 219 A O THR 219 1 A CG GLU 16 A CG GLU 16 1 Y 1 A CD GLU 16 A CD GLU 16 1 Y 1 A OE1 GLU 16 A OE1 GLU 16 1 Y 1 A OE2 GLU 16 A OE2 GLU 16 1 Y 1 A CD LYS 58 A CD LYS 58 1 Y 1 A CE LYS 58 A CE LYS 58 1 Y 1 A NZ LYS 58 A NZ LYS 58 1 Y 1 A CD LYS 116 A CD LYS 116 1 Y 1 A CE LYS 116 A CE LYS 116 1 Y 1 A NZ LYS 116 A NZ LYS 116 1 Y 1 A CG ASP 127 A CG ASP 127 1 Y 1 A OD1 ASP 127 A OD1 ASP 127 1 Y 1 A OD2 ASP 127 A OD2 ASP 127 1 Y 1 A CG GLU 225 A CG GLU 225 1 Y 1 A CD GLU 225 A CD GLU 225 1 Y 1 A OE1 GLU 225 A OE1 GLU 225 1 Y 1 A OE2 GLU 225 A OE2 GLU 225 1 Y 1 A MET 1 A MET 1 1 Y 1 A PRO 2 A PRO 2 1 Y 1 A GLU 3 A GLU 3 1 Y 1 A GLU 4 A GLU 4 1 Y 1 A THR 5 A THR 5 1 Y 1 A GLN 6 A GLN 6 1 Y 1 A THR 7 A THR 7 1 Y 1 A GLN 8 A GLN 8 1 Y 1 A ASP 9 A ASP 9 1 Y 1 A GLN 10 A GLN 10 1 Y 1 A PRO 11 A PRO 11 1 Y 1 A MET 12 A MET 12 1 Y 1 A GLU 13 A GLU 13 1 Y 1 A GLU 14 A GLU 14 1 Y 1 A GLU 15 A GLU 15 1 Y 1 A ALA 111 A ALA 111 1 Y 1 A LYS 112 A LYS 112 1 Y 1 A SER 113 A SER 113 1 Y 1 A ARG 226 A ARG 226 1 Y 1 A ASP 227 A ASP 227 1 Y 1 A LYS 228 A LYS 228 1 Y 1 A GLU 229 A GLU 229 1 Y 1 A A N CA ILE ILE 128 128 -0.269 0.020 1.459 1.190 N 1 A A CA C ILE ILE 128 128 0.271 0.026 1.525 1.796 N 1 A TYR 38 -38.16 135.64 1 A ASP 66 -152.28 84.46 1 A LYS 100 -36.68 -35.88 1 A ALA 117 -41.22 -73.45 1 A LEU 122 -69.41 74.21 1 A GLN 123 -16.69 -92.81 1 A ALA 124 -117.51 58.40 1 A ASP 127 78.77 162.16 1 A SER 129 -72.87 32.99 1 A GLN 133 -68.76 1.18 1 A ALA 166 67.11 -151.27 1 A ARG 182 -179.12 140.87 1 A THR 195 -67.78 4.68 43.2 -3.3036 0.0000 0.0000 16.0089 0.0000 -12.7053 0.2893 0.1949 0.1993 2.500 47.163 904 10079 4.8 98.97 0.64 1 1.31 MOLECULAR REPLACEMENT 28.42 0.90 1.11 INTERNAL STRUCTURE ML FLAT BULK SOLVENT MODEL 55.173 0.343 2.500 47.163 107 1747 24 0 1616 0.011 1667 1.354 2251 18.967 599 0.081 257 0.007 285 0.3432 0.2717 2.6567 181 2899 98.00 0.3344 0.2371 2.8618 145 3020 99.00 0.2800 0.2089 3.1497 135 2987 99.00 0.2864 0.1745 3.6054 159 2990 100.00 0.2355 0.1479 4.5418 136 3012 99.00 0.2551 0.1792 47.1717 148 2952 98.00 49.7 2.50 56.00 2YI5 10079 0.0 0.08 1 12.20 3.4 99.6 0.52 2.50 2.64 2.30 1 3.5 99.6 refinement PHENIX (PHENIX.REFINE) data reduction MOSFLM data scaling SCALA phasing PHASER HEAT SHOCK PROTEIN HSP 90-ALPHA Structural characterization of 5-Aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors. 1 N N 2 N N 3 N N A GLN 23 A GLN 23 HELX_P A THR 36 A THR 36 1 1 14 A GLU 42 A GLU 42 HELX_P A ASP 66 A ASP 66 1 2 25 A PRO 67 A PRO 67 HELX_P A GLY 73 A GLY 73 5 3 7 A THR 99 A THR 99 HELX_P A THR 109 A THR 109 1 4 11 A GLY 114 A GLY 114 HELX_P A LEU 122 A LEU 122 1 5 9 A ILE 131 A ILE 131 HELX_P A GLY 135 A GLY 135 5 6 5 A VAL 136 A VAL 136 HELX_P A LEU 143 A LEU 143 5 7 8 A GLN 194 A GLN 194 HELX_P A LEU 198 A LEU 198 5 8 5 A GLU 199 A GLU 199 HELX_P A GLN 212 A GLN 212 1 9 14 CHAPERONE CHAPERONE, ATPASE HS90A_HUMAN UNP 1 P07900 1 229 2YI5 1 229 P07900 A 1 1 229 8 anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel parallel A VAL 17 A VAL 17 A ALA 21 A ALA 21 A SER 169 A SER 169 A THR 174 A THR 174 A TYR 160 A TYR 160 A SER 164 A SER 164 A ALA 145 A ALA 145 A LYS 153 A LYS 153 A GLY 183 A GLY 183 A LEU 190 A LEU 190 A THR 88 A THR 88 A ASP 93 A ASP 93 A ILE 78 A ILE 78 A ASN 83 A ASN 83 A ILE 218 A ILE 218 A LEU 220 A LEU 220 BINDING SITE FOR RESIDUE YI5 A 1226 Software 11 A ASN 51 A ASN 51 11 1_555 A SER 52 A SER 52 11 1_555 A ALA 55 A ALA 55 11 1_555 A ASP 93 A ASP 93 11 1_555 A GLY 97 A GLY 97 11 1_555 A MET 98 A MET 98 11 1_555 A PHE 138 A PHE 138 11 1_555 A THR 184 A THR 184 11 1_555 A VAL 186 A VAL 186 11 1_555 A HOH 2030 C HOH 11 1_555 A HOH 2056 C HOH 11 1_555 20 C 2 2 21